Clinical Trials Sponsored by Sanofi China

Total 8235 results

Sanofi

Active, not recruiting

A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple Sclerosis

Multiple Sclerosis

Belgium, Bulgaria, Canada, Chile, China, France, Germany, Italy, Poland, Spain
Sanofi

Completed

Pharmacokinetic Study to Compare Itepekimab Exposure When Administered With an Autoinjector Versus Prefilled Syringe

Chronic Obstructive Pulmonary Disease

United States
Sanofi

Completed

Sutimlimab (BIVV009) for the Adult Participants With Cold Agglutinin Disease (CAD) Who Have Completed Phase 3 Studies (CARDINAL or CADENZA) in Japan

Cold Agglutinin Disease

Japan
Sanofi

Completed

Study of Drug-drug Interaction of the Effects of Gemfibrozil and Rifampicin on SAR442168 in Healthy Adult Subjects

Multiple Sclerosis

United States
Sanofi

Terminated

Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment (TRENT)

Type 2 Diabetes Mellitus | Renal Impairment

United States, Czechia, Hungary, Poland, Serbia
Sanofi

Completed

An Observational Study on Teriflunomide-exposed Pregnancies

Multiple Sclerosis

United States, Canada
Sanofi

Completed

Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia A

Hemophilia A

Bulgaria
Sanofi

Terminated

Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia (wAIHA)

Warm Autoimmune Hemolytic Anemia (wAIHA)

United Kingdom, Belgium, Netherlands, France, United States, Germany, Hungary, Italy
Sanofi

Terminated

Safety, Pharmacokinetics, and Preliminary Efficacy of Isatuximab in Patients Awaiting Kidney Transplantation

Immune System Disorder

United States, Spain
Sanofi

Completed

A PK Comparability Study of Two Different Amlitelimab Drug Products in Healthy Participants

Healthy Volunteers

United States
Sanofi

Active, not recruiting

Safety and Efficacy of Hectorol in Pediatric Patients With Chronic Kidney Disease Stage 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis

Secondary Hyperparathyroidism-Chronic Kidney Disease

United States, Chile
Sanofi

Completed

Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra®) in Subjects Aged 6 to 35 Months

Influenza

Korea, Republic of
Sanofi

Completed

To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis (SAFE)

Relapsing Multiple Sclerosis

India
Sanofi

Withdrawn

To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry Disease (BCLEAR1)

Fabry Disease
Sanofi

Completed

Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Renal Impairment Compared to Healthy Participants

Renal Impairment

United States, Germany
Sanofi

Completed

Mobilization of Stem Cells With AMD3100 (Plerixafor) in Combination With G-CSF in Multiple Myeloma Patients

Autologous Haematopoietic Stem Cell Transplant

China
Sanofi

Completed

Efficacy and Safety of FIRTECH in Patients With Mild to Moderate Acute Low Back Pain (IRPATCH)

Low Back Pain

Germany, Italy
Sanofi

Completed

Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients (inRange)

Type 1 Diabetes Mellitus

Turkey, Netherlands, Brazil, United States, Germany, Hungary, United Kingdom
Sanofi

Approved for marketing

Compassionate Use Program for Olipudase Alfa Enzyme Replacement Therapy for Patients With Chronic Acid Sphingomyelinase Deficiency (ASMD)

Sphingomyelin Lipidosis
Sanofi

Terminated

Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer (AMEERA-4)

Breast Cancer

France, Belgium, United States, Italy, Japan, Puerto Rico, Russian Federation, Spain, Ukraine
Sanofi

Completed

Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent (CARD)

Prostate Cancer Metastatic

United Kingdom, Austria, Belgium, Czechia, France, Germany, Greece, Iceland, Ireland, Italy, Netherlands, Norway, Spain
Sanofi

Terminated

Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies

Prostate Cancer | Non-small Cell Lung Cancer

Taiwan, United States, France, Italy, United Kingdom
Sanofi

Completed

First-in-human Study to Assess Safety and Tolerability of a Single Subcutaneous Dose of SAR441255 in Lean to Overweight Subjects

Overweight | Healthy Subjects

United States
Sanofi

Completed

A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma

Plasma Cell Myeloma

United States, Czechia, France
Sanofi

Completed

A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19

Corona Virus Infection

Mexico, Argentina, Brazil, Chile, Russian Federation
Sanofi

Completed

Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan (LixiRam)

Diabetes Mellitus, Type 2

Israel, India, Kuwait, Turkey
Sanofi

Completed

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulins in Insulin Naïve Patients Initiating Insulin (Reach-Control)

Diabetes Mellitus, Type 2

Germany, Spain, Brazil, France, Ireland, Romania, United Kingdom
Sanofi

Completed

A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)

Type 2 Diabetes Mellitus

Mexico, South Africa, United States, Mauritius, Spain, Turkey
Sanofi

Completed

Comparison of Pharmacodynamic Effects of Sotagliflozin and Empagliflozin in T2DM Patients With Mild to Moderate Hypertension

Diabetes Mellitus

Germany
Sanofi

Completed

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulin in Patients Already Using Basal Insulin (REGAIN CONTROL)

Diabetes Mellitus, Type 2

Italy, Ireland, Spain, Greece, Finland, Romania, Brazil, United Kingdom, France, Switzerland
Sanofi

Completed

Effect of Rifampicin on the Pharmacokinetics and Pharmacodynamics of Sotagliflozin

Diabetes Mellitus

France
Sanofi

Completed

Evaluation of the Efficacy and Safety of Insulin Glargine 300 U/mL in Patients With Type 2 Diabetes Mellitus Uncontrolled on Other Kinds of Insulin (ARTEMIS-DM)

Type 2 Diabetes Mellitus

Argentina, Colombia, Egypt, Hong Kong, India, Indonesia, Lebanon, Malaysia, Peru, Philippines, Saudi Arabia, South Africa, Thailand, Turkey
Sanofi

Completed

Study to Determine Absorption, Metabolism, and Excretion of [14C]-SAR439859, and to Assess Absolute Oral Bioavailability of Amcenestrant (SAR439859), in Healthy Post-menopausal Women

Breast Cancer | Healthy Volunteers

United Kingdom
Sanofi

Completed

Study Evaluating the Efficacy and Safety of Fexofenadine in Subjects Suffering From Seasonal Allergic Rhinitis in Presence of Pollutants (FEXPOLSAR)

Rhinitis Seasonal

Canada
Sanofi

Completed

A Study to Compare Pharmacokinetics (PK) and Pharmacodynamics (PD) of SAR341402 to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus

Type 1 Diabetes

Germany
Sanofi

Completed

A Bioequivalence Study Testing Two Formulations of Sotagliflozin in Healthy Male and Female Subjects Under Fasted Conditions

Type 2 Diabetes Mellitus | Healthy Subjects

United States
Sanofi

Terminated

Hydroxychloroquine in Outpatient Adults With COVID-19

Coronavirus Infection

United States, Belgium, France, Netherlands
Sanofi

Terminated

Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Diet and Exercise

Type 2 Diabetes Mellitus

China
Sanofi

Completed

Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen

Neoplasm Malignant

Spain, Belgium, United States, France
Sanofi

Terminated

Phase I/IIA Study of SAR422459 in Participants With Stargardt's Macular Degeneration

Stargardt's Disease

United States, France
Sanofi

Completed

Comparison of Sotagliflozin Prototype Tablets With Reference Tablet in Healthy Subjects

Type 2 Diabetes Mellitus | Type 1 Diabetes Mellitus

Germany
Sanofi

Completed

Evaluation of the Relationship Between ABCG2 Mutation and Teriflunomide Exposure and Safety in Chinese RMS Patients Treated With Teriflunomide 14 mg Once Daily for 24 Weeks (TERI-PK)

Multiple Sclerosis

China
Sanofi

Terminated

Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy)

Type 1 Diabetes Mellitus

United States, Canada
Sanofi

Completed

Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus (EDITION JUNIOR)

Type 1 Diabetes Mellitus

France, Czechia, Chile, Israel, Spain, Hungary, Mexico, Serbia, Japan, Canada, Brazil, Sweden, Denmark, Argentina, United States, Bulgaria, Germany, Italy, Latvia, North Macedonia, Poland, Romania, Russian Federation, United Kingdom
Sanofi

Completed

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin (EDITION I)

Type 2 Diabetes Mellitus

United States, South Africa, Canada, Czechia, Estonia, Finland, France, Germany, Hungary, Latvia, Mexico, Netherlands, Romania
Sanofi

Completed

A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Germany, Spain, United States, Canada, Czechia, Hungary, Mexico, Russian Federation
Sanofi

Completed

Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis (ESTAIR)

Idiopathic Pulmonary Fibrosis

Czechia, Korea, Republic of, Mexico, Israel, Spain, Greece, Chile, Canada, Colombia, Turkey, Denmark, France, United States, Argentina, Australia, Germany, Italy, Portugal, United Kingdom
Sanofi

Completed

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy (EDITION II)

Type 2 Diabetes Mellitus

United States, Finland, South Africa, Canada, Mexico, Chile, Spain, Russian Federation, France, Germany, Hungary, Portugal, Romania
Sanofi

Terminated

Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia (ISLAY)

T-cell Type Acute Leukemia-Precursor | T-lymphoblastic Lymphoma/Leukaemia

Hungary, United States, Finland, France, Italy, Lithuania, Russian Federation
Sanofi

Completed

A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma

Neoplasm Malignant

United States

3

Subscribe